Lv3
350 积分 2025-02-20 加入
Putting Pharmacokinetics and Pharmacodynamics to Work in Drug Discovery
9小时前
已完结
Navigating First‐in‐Human and Early‐Phase Patient Studies: Study Designs, Risk Mitigation, and Population Selection Challenges
16天前
已完结
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
29天前
已完结
First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors
1个月前
已关闭
Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia
1个月前
已完结
Distribution Characteristics and Impacting Factors of Drug CYP Enzymes and Transporters in the Gastrointestinal Tract of Chinese Healthy Subjects
1个月前
已完结
Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7
1个月前
已完结
A comparison of methods for the estimation of retroviral burden
2个月前
已关闭
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas
2个月前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
3个月前
已完结
皖公网安备34019202002308
